“By enabling researchers to sample and assess each of the diverse intestinal ecosystems separately and directly for the first time, CapScan opens the door to a new era of microbiome research.”ĬapScan is a non-invasive, ingestible collection device that is about the size of a vitamin pill. “Our research confirms that, up until now, studies of the gut microbiome have really been studies of the stool microbiome, which missed out on most of the biological activity in our intestinal tract,” said Dari Shalon, Ph.D., founder and CEO of Envivo Bio.
Additionally, their findings detect and measure microbes and metabolites that are not present in stool or are inaccessible via endoscopic sampling. The researchers report significant differences in microbiome composition, gene-class abundance, prophage induction, and the host proteome along various regions of the human intestine. In the Nature article, titled “Profiling the human intestinal environment under physiological conditions,” researchers from multiple universities and institutions describe CapScan’s capabilities to measure microbial, viral, proteomic, and bile acid profiles within the human intestines during normal digestion. Because the intestinal tract is regionally heterogenous, traditional sampling methods such as endoscopic biopsies and stool collection offer limited utility in understanding how intestinal gut microbes and metabolites impact human physiology. Increasingly, research shows that the gut microbiome and metabolome play a critical role in numerous diseases as well as in food digestion, immune system regulation, and protection against pathogens, all of which have implications for human health and disease.
Findings from the landmark study suggest that CapScan, the first and only device of its kind, has the potential to accelerate microbiome-related research and biopharmaceutical drug-discovery and development programs. SAN FRANCISCO-( BUSINESS WIRE)-Envivo Bio, a biotech company advancing the gut microbiome and metabolome field, announced that new data published in Nature show the company’s proprietary CapScan® intestinal sampling device can non-invasively and accurately profile the human gut microbiome and metabolome under physiological conditions for the first time.
0 kommentar(er)
